Patent ID: 8273544

Claim:
A method of drug screening, said method comprising: classifying one or more hematopoietic cells associated with acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasms in an individual by a method comprising: a) subjecting a cell population comprising said one or more hematopoietic cells from said individual to a test compound and a plurality of modulators in a plurality of cultures, b) characterizing at least three pathways in one or more cells from said plurality of cultures by determining an activation level of at least one activatable element within the at least three pathways, wherein i) at least two of the pathways being characterized are an apoptosis and a DNA damage pathway, ii) the modulators activate or inhibit one or more of said at least three pathways being characterized, and c) classifying said one or more hematopoietic cells into groups comprising response or non-response to therapeutic treatment, or risk of relapse based on said pathways characterization, said classification enabling a decision regarding the test compound and its therapeutic potential for the treatment of acute leukemia, myelodysplastic syndrome or myeloproliferative neoplasms, wherein said decision is based on said classification of said cells.